ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Autolus Therapeutics PLC

Autolus Therapeutics PLC (AUTL)

1,53
-0,13
(-7,83%)
Geschlossen 07 Juni 10:00PM
1,5481
0,0181
(1,18%)
Nach Börsenschluss: 1:39AM

Autolus Therapeutics PLC (AUTL) Aktie

Professionelle Tools für Privatanleger.

Premium

Wichtige Statistiken und Details

Current Price
1,5481
( -6,74% )
Gebot
1,21
Fragen
1,84
Volumen
1.461.945
1,505 Tagesbereich 1,66
1,175 52-Wochen-Bereich 2,70
Marktkapitalisierung
Handelsende
1,66
Handelsbeginn
1,66
Letzte Trade
50
@
1.5463
Letzter Handelszeitpunkt
Finanzvolumen
US$ 2.267.199
VWAP
1,5508
Durchschnittliches Volumen (3 Mio.)
US$ 1.626.188
Ausgegebene Aktien
266.143.286
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-1,72
Gewinn pro Aktie (EPS)
-1,09
Erlöse (LTM)
92,62M
Nettogewinn (LTM)
-288,97M

Über Autolus Therapeutics PLC

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with... Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Website
Hauptsitz
London, United Kingdom
Gegründet
2026
Autolus Therapeutics PLC is listed in the Healthcare sector of the NASDAQ with ticker AUTL. The last closing price for Autolus Therapeutics was US$1,66. Over the last year, Autolus Therapeutics shares have traded in a share price range of US$ 1,175 to US$ 2,70.

Autolus Therapeutics currently has 266.143.286 shares in issue. The market capitalisation of Autolus Therapeutics is US$412,02 million. Autolus Therapeutics has a price to earnings ratio (PE ratio) of -1.72.

AUTL Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.2219-12.53672316381.771.88781.5116853321.75517134DR
4-0.0719-4.438271604941.621.951.430117358531.70228428DR
120.07815.312925170071.471.951.17516155381.53243339DR
26-0.0319-2.018987341771.582.071.17518427241.58043816DR
52-0.5519-26.2809523812.12.71.17524765101.64864926DR
156-1.3619-46.80068728522.917.451.10516918942.63276531DR
260-4.9619-76.21966205846.518.231.10512819113.10219264DR

AUTL - Frequently Asked Questions (FAQ)

What is the current Autolus Therapeutics PLC share price?
The current share price of Autolus Therapeutics PLC is US$ 1,5481
How many Autolus Therapeutics PLC shares are in issue?
Autolus Therapeutics PLC has 266.143.286 shares in issue
What is the market cap of Autolus Therapeutics PLC?
The market capitalisation of Autolus Therapeutics PLC is USD 412,02M
What is the 1 year trading range for Autolus Therapeutics PLC share price?
Autolus Therapeutics PLC has traded in the range of US$ 1,175 to US$ 2,70 during the past year
What is the PE ratio of Autolus Therapeutics PLC?
The price to earnings ratio of Autolus Therapeutics PLC is -1,72
What is the cash to sales ratio of Autolus Therapeutics PLC?
The cash to sales ratio of Autolus Therapeutics PLC is 5,37
What is the registered address of Autolus Therapeutics PLC?
The registered address for Autolus Therapeutics PLC is The Mediaworks, London, Greater London, W12 7FP
What is the Autolus Therapeutics PLC website address?
The website address for Autolus Therapeutics PLC is www.autolus.com
Which industry sector does Autolus Therapeutics PLC operate in?
Autolus Therapeutics PLC operates in the Biotechnology & Life Sciences sector

AUTL Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen